Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Earnings release
confidence 95%
filed 2026-08-14
EX-99.5
This is a press release dated August 12, 2026, announcing Denison's "Financial and Operational Results for Q2 2026." The exhibit discloses condensed consolidated financial statements and MD&A for the three and six months ended June 30, 2026, filed with SEDAR+, EDGAR, and the company website. The release highlights Q2 financial results including uranium sales generating $91.6 million in gross proceeds and a $64.1 million realized gain, along with operational progress at the Phoenix ISR uranium mine. This is a discrete earnings announcement, not a periodic financial report itself.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
This is a clear earnings release disclosing Lifeloc's operating results for the quarter ended June 30, 2026. The Item 2.02 filing announces quarterly net revenue of $2.445 million and a net loss of $(134) thousand, with detailed financial statements (balance sheet, income statement, cash flows, and equity changes) attached as Exhibit 99.1. The press release explicitly states "Lifeloc Reports Second Quarter 2026 Results" and provides comparative results to the prior year period, which is the hallmark of an earnings disclosure.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-08-14
Item 8.01
The filing discloses multiple governance events: (1) appointment of Scott Mager as General Counsel on 5/19/2026 and as Director on 6/15/2026; (2) appointment of Richard Kaiser as interim CEO on 6/17/2026; and (3) establishment of an Advisory Board with appointments of Stuart Yarbrough and Edward Mathias. While individual appointments could be classified as exec_appointment, the disclosure centers on a comprehensive governance restructuring involving leadership changes (interim CEO appointment), board expansion (new director), and advisory board formation. This is material as it reflects significant changes in the company's leadership and governance structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-14
Item 1.01
EDAP TMS entered into an underwriting agreement on August 11, 2026 for a public offering of 8,425,000 ADSs at $4.75 per share, with expected net proceeds of approximately $37.1 million. This is a registered public offering of equity securities that will dilute existing shareholders. While technically a registered offering (not an unregistered private placement), the core event is the issuance of a material amount of new equity capital, which is material to investors assessing the company's capital structure and ownership dilution.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-14
EX-99.1
This press release announces an expanded strategic partnership with Uber to deploy over 2,000 robotaxis across five European cities plus the Middle East, building on an existing May 2025 collaboration. The announcement describes a material operational and commercial milestone—scaling from a single city (Zagreb) to multiple markets with a defined deployment model combining Pony AI's L4 autonomous driving technology, Uber's mobility platform, and local fleet operations. While this is a significant business development, it does not fit the discrete event categories of M&A activity (no acquisition, merger, or change of control), debt issuance, or other named financial events; rather, it is a material operational/strategic partnership expansion that affects the company's commercialization trajectory and market presence.
View raw filing on EDGAR →
6-K
Financial Other
confidence 85%
filed 2026-08-14
EX-99.1
This announcement discloses an adjustment to the exchange price and exchange ratio of Alibaba's zero coupon exchangeable bonds due 2032, triggered by Alibaba Health's declaration of dividends (final dividend of RMB0.0595 and special dividend of RMB0.1352 per share). The exchange price decreased from HK$6.23 to HK$5.92 per AH Share, and the exchange ratio increased from 160,513.6 to 168,918.9 AH Shares per HK$1,000,000 principal, increasing the total exchangeable shares from 1.93 billion to 2.03 billion. This is a material financial event affecting the terms of a significant debt instrument and the potential dilution to Alibaba Health shareholders, though it does not fit the specific categories of debt_issuance (which concerns creation of new obligations) or dilutive_issuance (which concerns equity sales). It is best classified as a financial event that does not fit a named category.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-08-14
Item 4.01
The Board accepted the resignation of PricewaterhouseCoopers AG, Switzerland as the independent registered public accounting firm and appointed PricewaterhouseCoopers LLP, United States as the new auditor, effective August 14, 2026. This is a direct auditor change disclosed under Item 4.01, with no disagreements or reportable events noted, driven by the Company's status as a US domestic reporting company and increasing US operations.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-14
EX-99.1
This is a press release announcing RLX Technology's unaudited second quarter 2026 financial results, including net revenues of RMB1,010.5 million (up 14.8% YoY), gross margin of 35.4%, and net income of RMB222.0 million. The document explicitly states "RLX Technology Announces Unaudited Second Quarter 2026 Financial Results" and provides comprehensive quarterly financial metrics, management commentary, and forward guidance. This is a discrete earnings announcement, not a periodic financial report filing.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-14
EX-99.1
This exhibit is a press release announcing CASI Pharmaceuticals' first-half 2026 business and financial results, dated August 14, 2026. It discloses revenues of $9.8 million, a net loss of $20.0 million, cash position of $3.8 million, and includes unaudited condensed consolidated balance sheets and statements of operations. The disclosure is material as it reports interim financial performance and includes significant operational updates (clinical trial progress, Nasdaq delisting, OTCQB quotation, and a $15 million convertible note financing).
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02. The press release discloses financial results including R&D expenses ($4.0M vs $5.8M YoY), G&A expenses ($2.6M vs $3.1M YoY), net loss ($6.5M vs net income of $4.2M in prior year), and EPS of $(0.69), along with consolidated balance sheets and statements of operations. The filing also includes material business updates on TTI-109 clinical progress and UC indication selection, which are integral to the earnings announcement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
The filing discloses Outlook Therapeutics' third quarter fiscal year 2026 financial results (ended June 30, 2026), including net loss of $20.3 million ($0.15 per share) and adjusted net loss of $10.9 million ($0.09 per share). The press release in Exhibit 99.1 is a standard earnings announcement that reports quarterly financial results alongside a business update on the FDA approval of LYTENAVA and commercial launch preparations. This is a material earnings disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
This is a classic earnings release disclosure under Item 2.02. The company announced financial results for the fiscal first quarter ended June 30, 2026, including R&D expenses ($49.3M), SG&A expenses ($19.0M), and net loss ($69.8M), along with balance sheet data and cash position. The news release is furnished as Exhibit 99.1 and includes material corporate updates (FDA approval of TUDRIQEV, executive appointment, financing completion). This is material to investors as it provides quarterly financial performance and significant operational milestones.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-14
Item 8.01
Outlook Therapeutics entered into an underwriting agreement on August 12, 2026 for a public offering of 55,555,556 shares of common stock and accompanying warrants at $0.99 per share, with estimated gross proceeds of approximately $55.0 million. This is a registered public offering of equity securities that will dilute existing shareholders, fitting the dilutive_issuance category. While technically a registered offering (not unregistered), the core event—issuance of a substantial number of new equity securities to raise capital—aligns with the dilutive_issuance taxonomy, which captures material equity capital raises at small- and mid-cap issuers.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-14
This is a press release dated August 13, 2026 announcing Turkcell's second quarter 2026 financial results. The document contains consolidated financial statements (revenue, EBITDA, EBIT, net income), operational metrics (subscriber additions, churn rates), and forward-looking guidance for full-year 2026. The enclosure explicitly states it is "a press release dated August 13, 2026 announcing the release of the registrant's second quarter 2026 results," which is the hallmark of an earnings release disclosure.
View raw filing on EDGAR →
8-K
Going Concern
confidence 92%
filed 2026-08-14
Item 8.01
Trinseo PLC disclosed on August 7, 2026 that its net assets have fallen to half or less of its called-up share capital, triggering a mandatory extraordinary general meeting under Section 1111 of the Irish Companies Act 2014. This disclosure signals substantial financial distress and raises material questions about the company's ability to continue as a going concern, even though the filing does not use that exact phrase. The triggering of a statutory capital-impairment meeting is a strong indicator of solvency concerns material to investors.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-08-14
Item 8.01
Steel Dynamics' board declared a third quarter cash dividend of $0.53 per common share, payable to shareholders of record on September 30, 2026, and payable on or about October 9, 2026. This is a straightforward dividend distribution disclosure that would be material to investors assessing the company's capital allocation and shareholder returns.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-14
Item 3.02
The Company issued 24,649 C-LTIP Units (convertible to OP Units and ultimately redeemable for Class A Common Stock) on August 13, 2026, in partial satisfaction of the Manager's base management fee and executive compensation obligations. The issuance was unregistered, relying on Section 4(a)(2) and Regulation D exemptions. This is a dilutive equity issuance to service management fees and executive compensation, materially affecting shareholder ownership and voting power.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-14
EX-99.1
This is an announcement that JinkoSolar will release its unaudited financial results for Q2 2026 (ended June 30, 2026) on August 26, 2026, accompanied by a management earnings conference call. Although the actual results are not disclosed in this exhibit, the announcement of the forthcoming earnings release and conference call is the standard form of earnings disclosure for public companies and would materially affect investor assessment of the registrant's financial performance.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-08-14
Item 8.01
The Company issued $1.35 billion in aggregate principal amount of Medium-Term Notes in two tranches on August 14, 2026: $300 million of floating-rate notes due 2029 and $1.05 billion of 4.650% fixed-rate notes due 2029, pursuant to a registered Form S-3. This is a material creation of direct financial obligations and constitutes a debt issuance under Item 2.03 (though disclosed under Item 8.01).
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-08-14
IBM filed this 8-K to incorporate by reference debt securities documentation into its Form S-3 registration statement. The filing discloses an underwriting agreement dated August 10, 2026 for C$2,750,000,000 aggregate principal amount of debt securities, including forms of 4.100% Notes due 2030 and 4.750% Notes due 2034. This represents the creation of new direct financial obligations through a debt issuance, which is material to investors assessing the registrant's capital structure and leverage.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 98%
filed 2026-08-14
Item 1.01
O'Reilly Automotive issued $1.6 billion in aggregate principal amount of senior notes across three tranches (2029, 2031, and 2037 maturities) on August 14, 2026. This is a material creation of direct financial obligations governed by supplemental indentures, clearly falling under debt_issuance. The magnitude and multi-tranche structure make this material to investors assessing the company's capital structure and financial obligations.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-14
Item 2.02
This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02 Results of Operations and Financial Condition. The press release (Exhibit 99.1) discloses quarterly financial results including balance sheet, statement of operations, net loss per share ($0.40 basic and diluted), and key operational metrics. The filing explicitly states "issued a press release reporting earnings for the quarter ended June 30, 2026."
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-14
Item 5.07
This Item 5.07 disclosure reports the results of CytoSorbents' 2026 Annual Meeting of Stockholders held on August 13, 2026, including voting outcomes on five proposals: election of five directors, advisory approval of named executive officer compensation, ratification of the independent auditor (WithumSmith+Brown, PC), approval of a reverse stock split (1-for-5 to 1-for-20 ratio), and approval of an adjournment provision. All proposals passed. The disclosure includes detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal, which is the standard format for shareholder vote results under Item 5.07.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
This is a standard earnings release disclosing Q2 2026 financial results for Quoin Pharmaceuticals. The filing explicitly states "On August 14, 2026 Quoin Pharmaceuticals Ltd. (the 'Company') issued a press release announcing its financial results for the quarter ended June 30, 2026," with the press release furnished as Exhibit 99.1. The exhibit contains consolidated balance sheets, statements of operations, and loss per ADS metrics for the periods ended June 30, 2026 and 2025, along with operational highlights. This is a material disclosure affecting investor assessment of the company's financial condition and operational progress.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-14
Item 5.02
Dr. Lorence H. Kim resigned from the Board of Directors effective immediately on August 13, 2026, due to his appointment as Chief Financial Officer of Commonwealth Fusion Systems, Inc. This is a clear departure of a director from the registrant's board, making it a material executive departure event that would affect a reasonable investor's assessment of board composition and governance.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 98%
filed 2026-08-14
Item 8.01
The Company completed a public offering of $90 million aggregate principal amount of 9.600% Senior Notes due 2031 on August 14, 2026, pursuant to an underwriting agreement with major investment banks. This is a clear creation of a new direct financial obligation—a debt issuance—with net proceeds of approximately $86.6 million intended for general corporate purposes, asset acquisition, or debt repayment. The detailed disclosure of terms, underwriters, indenture provisions, and use of proceeds is characteristic of material debt issuance disclosures under Item 8.01.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-14
Vuzix entered into an Open Market Sales Agreement with Jefferies on August 14, 2026, establishing an at-the-market offering program for up to $100,000,000 of common stock. This is a dilutive equity issuance under an ATM program, which is material to investors as it signals potential capital raising and shareholder dilution. The filing explicitly discloses the sales agreement, commission structure (3.0%), and prospectus supplement filed under Rule 424(b).
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-14
Item 1.01
PSQ Holdings entered into a securities purchase agreement for a private placement of 361,385 shares of Class A common stock at $3.60 per share, generating $1.3 million in gross proceeds. The transaction is exempt from registration under Section 4(a)(2) and Regulation D Rule 506, with purchasers including company directors represented as accredited investors.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-08-14
Item 1.01
VICI LP completed a $1.75 billion debt offering on August 14, 2026, issuing $900 million of 5.400% Notes due 2031 and $850 million of 5.750% Notes due 2036 pursuant to a Fifth Supplemental Indenture. The proceeds are intended to refinance approximately $1.75 billion of maturing debt due in 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
This is a standard quarterly earnings release for Q2 2026 ended June 30, 2026, disclosing financial results including net loss of $3.9 million, cash position of $0.2 million, and operating expenses. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings announcements. The filing includes consolidated balance sheet and comprehensive loss statements for the period.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-14
Item 5.02
Three directors—Donald Fell, Michael Peterson, and Suren Ajjarapu—resigned from the Board effective immediately on August 10, 2026. The filing discloses the departure of multiple board members, which is material to investors' assessment of governance and board composition. The stated reason (personal reasons, no disagreement) does not diminish materiality of the event itself.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 97%
filed 2026-08-14
Item 5.07
RE/MAX Holdings shareholders approved two material merger proposals at a special meeting held on August 14, 2026: approval of issuance of Class A common stock to RIHI stockholders (26,660,357 votes for, 169,623 against) and adoption of the Merger Agreement with The Real Brokerage Inc. (26,681,107 votes for, 149,866 against), creating the combined 'Real REMAX Group' entity. Shareholders of both Real and RE/MAX Holdings approved the transaction, with Real shareholders voting approximately 99.0% in favor and RE/MAX Holdings shareholders voting 78.8% of voting power in favor.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 7.01
Traws Pharma disclosed Q2 2026 financial results via press release on August 14, 2026, reporting zero revenue, R&D expenses of $1.1M, G&A expenses of $3.5M, and a net loss of $3.0M for the quarter ($0.16 per share), with cash and equivalents of $5.0M as of June 30, 2026.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 75%
filed 2026-08-14
The 6-K discloses an amendment to an existing convertible promissory note originally issued August 4, 2025, extending its maturity date to November 5, 2026, and adding a 2.5% extension fee ($54,197.87) to the outstanding balance. While technically an amendment rather than a new issuance, the extension and fee addition materially modify the Company's direct financial obligation and are disclosed as a material transaction with an accredited investor.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-14
Item 3.01
Adagio Medical received a deficiency letter from Nasdaq on August 13, 2026, notifying the company that it failed to maintain the minimum stockholders' equity requirement of $2,500,000 for continued listing on the Nasdaq Capital Market. The company reported negative stockholders' equity of $(415,000) as of June 30, 2026, and does not meet alternative quantitative standards. The company has 45 calendar days to submit a compliance plan or face potential delisting. This is a clear notice of failure to satisfy a continued listing rule under Item 3.01.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-08-14
EX-99.1
This is an at-the-market (ATM) sales agreement executed on August 14, 2026, authorizing Satellos Bioscience to issue and sell up to $50,000,000 of common shares through Leerink Partners LLC. The agreement explicitly permits sales "at market prices prevailing at the time of sale" and references an effective Registration Statement filed August 11, 2026. This is a dilutive equity issuance that would materially affect existing shareholders through potential share dilution and capital raising activity.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-08-14
Item 5.02
The disclosure centers on a Restricted Stock Transfer Agreement between Mithaq Capital (controlling shareholder) and Muhammad Asif Seemab (Vice Chairman, President, and Interim CEO) for 500,000 restricted shares with performance-based vesting tied to market capitalization milestones and continued employment. This is a compensatory arrangement for a named executive officer, fitting the exec_compensation category despite the technical structure as a transfer from the controlling shareholder rather than a direct company grant.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 97%
filed 2026-08-14
Item 2.03
Realty Income issued $1.0 billion principal amount of 3.750% Convertible Senior Notes due 2031 on August 14, 2026, creating a direct financial obligation. The convertible notes are senior, unsecured securities with conversion rights for up to 16,157,600 shares of common stock, and net proceeds of approximately $981.9 million were allocated to general corporate purposes including debt repayment, property acquisition, and share repurchases.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-08-14
Item 1.01
Hallador Energy entered into a Third Amendment to its Credit Agreement on August 11, 2026, modifying the definition of 'EBITDA' to permit add-backs of up to $10 million in power purchase agreement exclusivity payments. This material modification to the credit facility affects covenant compliance calculations and the registrant's direct financial obligations.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-14
Item 7.01
The filing discloses a proposed business combination between Cartesian Growth Corporation II (a SPAC) and InoBat AS, a Norwegian battery technology company. The 8-K Item 7.01 furnishes an investor presentation regarding this business combination and references CGC's intent to file a Form F-4 registration statement with proxy statements for shareholder approval. This is a material M&A transaction requiring shareholder vote and SEC registration, fitting the ma_activity classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-14
EX-99.1
Standard Lithium disclosed a maiden inferred resource estimate for its Franklin Project lithium-brine deposit in Texas, containing 406,000 tonnes of elemental lithium equivalent (2,159,000 tonnes of lithium carbonate equivalent). The NI 43-101 Technical Report presents geological and mineral resource data for this material operational asset, which is part of the company's joint venture with Equinor and central to its direct lithium extraction strategy.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-14
EX-99.6
Standard Lithium established an at-the-market (ATM) equity program permitting issuance of up to US$50 million of common shares from treasury to the public at the company's discretion under a shelf prospectus. The company has previously sold US$36 million under a prior ATM program and intends to continue raising capital through this mechanism, creating dilution risk for existing shareholders.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-08-14
Item 1.01
Riot Platforms' subsidiary Riot DC Logistics entered into a senior secured delayed-draw term loan credit agreement for $573.0 million on August 10, 2026, to fund equipment purchases and expenses for a 191 MW data center project at its Rockdale Facility.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-08-14
Item 8.01
Alexandria Real Estate Equities entered into an underwriting agreement on August 12, 2026 to issue $1,000,000,000 aggregate principal amount of 7.250% Series A Fixed-to-Fixed Reset Rate Junior Subordinated Notes due 2057. This is a material creation of a new direct financial obligation through debt issuance, disclosed under Item 8.01 with supporting press release. The size ($1 billion), terms, and use of proceeds (debt reduction, working capital, property acquisition) make this material to investors.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 8.01
The filing discloses quarterly and six-month financial results for the periods ended June 30, 2026, including net sales, operating losses, and net income/loss figures. The press release attached as Exhibit 99 announces these results, which is the hallmark of an earnings release disclosure under Item 8.01. The results show material declines in revenue (Q2 2026: $7.2M vs. Q2 2025: $10.4M) and significant operating losses, making this material to investors.
View raw filing on EDGAR →
6-K
Other material
confidence 72%
filed 2026-08-14
The Company cancelled 45,912,240 ordinary shares (15.3M from CENTRAL PLAINS LTD. and 30.6M from XY MANAGEMENT LIMITED) surrendered voluntarily for no consideration on July 8, 2026. This represents a material reduction in outstanding share count and capitalization structure. While share cancellations can be routine, the magnitude here (45.9M shares) and the involvement of two significant shareholders surrendering shares for no consideration suggests a material capital restructuring event that would affect a reasonable investor's assessment of ownership and equity value, but does not fit neatly into the standard taxonomy categories (not a dilutive issuance, dividend, or standard M&A activity).
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-14
EX-99.1
This exhibit comprises Qualified Person certificates and the cover/introduction pages of a "Carangas Project: NI 43-101 Technical Report and Preliminary Economic Assessment" dated July 16, 2026 (effective) and August 13, 2026 (report date). The document discloses a preliminary economic assessment (PEA) of a mineral project in Bolivia, which is a material operational/strategic milestone for a mining exploration company. While not a discrete event like M&A or a restatement, the completion and disclosure of a PEA represents a significant advancement in project development and would affect a reasonable investor's assessment of the registrant's asset value and operational prospects.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-14
Item 2.02
This is a straightforward earnings release for Q2 2026 ended June 30, 2026. The press release discloses key financial metrics including revenue of $7.0M (up 22% YoY), return to positive Adjusted EBITDA of $0.4M, and improved cash position exceeding $3M. The filing explicitly states the press release is being furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
This is a classic Item 2.02 earnings release. Galectin Therapeutics issued a press release on August 14, 2026 announcing financial results for the six months ended June 30, 2026, including condensed consolidated statements of operations and balance sheet data. The filing explicitly states the company "issued a press release announcing its results of operations and financial condition" and incorporates the press release by reference as Exhibit 99.1, which contains detailed quarterly financial highlights, net loss figures, and cash position disclosures typical of earnings announcements.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-14
Item 5.07
PDS Biotechnology held its Annual Meeting of Stockholders with voting results on four proposals: election of two Class B directors (Kamil Ali-Jackson and Ilian Iliev), approval of a Certificate of Incorporation amendment to increase authorized common shares, ratification of KPMG as independent auditor, and a non-binding advisory vote on named executive officer compensation.
View raw filing on EDGAR →